FORM 3
        
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

McKew John C.
2. Date of Event Requiring Statement (MM/DD/YYYY)
3/18/2020 

3. Issuer Name and Ticker or Trading Symbol

LUMOS PHARMA, INC. [(LUMO)]
(Last)        (First)        (Middle)

4200 MARATHON BLVD, SUITE 200
4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                          _____ 10% Owner
___X___ Officer (give title below)        _____ Other (specify below)
Chief Scientific Officer /
(Street)

AUSTIN, TX 78756      

(City)              (State)              (Zip)
5. If Amendment, Date Original Filed(MM/DD/YYYY)
 

6. Individual or Joint/Group Filing(Check Applicable Line)

_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)
2. Amount of Securities Beneficially Owned
(Instr. 4)
3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)
4. Nature of Indirect Beneficial Ownership
(Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 4)
2. Date Exercisable and Expiration Date
(MM/DD/YYYY)
3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)
4. Conversion or Exercise Price of Derivative Security5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)
6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy) 3/4/2017 (1)7/11/2026 Common Stock 81690.0 $4.82 D  
Stock Option (Right to Buy) 12/5/2018 (2)1/18/2028 Common Stock 9583.0 $2.45 D  
Stock Option (Right to Buy) 8/29/2018 (3)8/29/2028 Common Stock 6541.0 $2.45 D  

Explanation of Responses:
(1) The shares subject to the option became fully vested and exercisable March 4, 2020.
(2) One-fourth of the shares subject to the option vested and became exercisable on December 5, 2018, and thereafter the remainder of the shares subject to the option continue to vest in 36 substantially equal monthly installments, subject to the reporting person's continued service with the Issuer and subject to acceleration upon the occurrence of certain events.
(3) The shares subject to the option became fully vested and exercisable on the grant date, August 29, 2018.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
McKew John C.
4200 MARATHON BLVD
SUITE 200
AUSTIN, TX 78756


Chief Scientific Officer

Signatures
/s/ Ryan Trytten, attorney-in-fact3/30/2020
**Signature of Reporting PersonDate

NewLink Genetics (NASDAQ:NLNK)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more NewLink Genetics Charts.
NewLink Genetics (NASDAQ:NLNK)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more NewLink Genetics Charts.